JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Weber, W. A.
Right arrow Articles by Figlin, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Weber, W. A.
Right arrow Articles by Figlin, R.
Journal of Nuclear Medicine Vol. 48 No. 1 (Suppl) 36S-44S
© 2007 by Society of Nuclear Medicine

Monitoring Cancer Treatment with PET/CT: Does It Make a Difference?

Wolfgang A. Weber1 and Robert Figlin2

1 Department of Molecular and Medical Pharmacology, University of California, Los Angeles, California; and 2 Division of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Los Angeles, California

Correspondence: For correspondence or reprints contact: Wolfgang A. Weber, MD, Department of Molecular and Medical Pharmacology, UCLA, 10833 Le Conte Ave., Los Angeles, CA 90095. E-mail: wweber{at}mednet.ucla.edu

PET with the glucose analog 18F-FDG is increasingly being used to monitor the effectiveness of therapy in patients with malignant lymphomas and a variety of solid tumors. The use of integrated PET/CT instead of stand-alone PET for treatment monitoring poses some methodologic challenges for the quantitative analysis of PET scans but also provides the opportunity to integrate morphologic information and functional information. This integration may allow the definition of new parameters for assessment of the tumor response and will also facilitate the use of PET in research studies as well as in clinical practice. This review addresses how CT-based attenuation correction may affect the quantitative analysis of 18F-FDG PET scans and summarizes the results of recent studies with PET/CT for treatment monitoring for lung cancer and gastrointestinal stromal tumors. The review concludes with an outlook on how PET/CT could make a difference in drug development and clinical management for patients.

Key Words: PET • 18F-FDG • CT • tumor response • treatment monitoring • patient outcome

COPYRIGHT © 2006 by the Society of Nuclear Medicine, Inc.




This article has been cited by other articles:


Home page
Anticancer ResHome page
J. MONTEIL, N. MAHMOUDI, S. LEOBON, P.Y. ROUDAUT, A. EL BADAOUI, S. VERBEKE, L. VENAT-BOUVET, J. MARTIN, V. LE BRUN-LY, S. LAVAU-DENES, et al.
Chemotherapy Response Evaluation in Metastatic Colorectal Cancer with FDG PET/CT and CT Scans
Anticancer Res, July 1, 2009; 29(7): 2563 - 2568.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
L.-F. de Geus-Oei, D. Vriens, H. W.M. van Laarhoven, W. T.A. van der Graaf, and W. J.G. Oyen
Monitoring and Predicting Response to Therapy with 18F-FDG PET in Colorectal Cancer: A Systematic Review
J. Nucl. Med., May 1, 2009; 50(Suppl_1): 43S - 54S.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
R. L. Wahl, H. Jacene, Y. Kasamon, and M. A. Lodge
From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors
J. Nucl. Med., May 1, 2009; 50(Suppl_1): 122S - 150S.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
B. J. Krause, K. Herrmann, H. Wieder, and C. M. zum Buschenfelde
18F-FDG PET and 18F-FDG PET/CT for Assessing Response to Therapy in Esophageal Cancer
J. Nucl. Med., May 1, 2009; 50(Suppl_1): 89S - 96S.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
B. Zhao, L. H. Schwartz, and S. M. Larson
Imaging Surrogates of Tumor Response to Therapy: Anatomic and Functional Biomarkers
J. Nucl. Med., February 1, 2009; 50(2): 239 - 249.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
M. R. Benz, V. Evilevitch, M. S. Allen-Auerbach, F. C. Eilber, M. E. Phelps, J. Czernin, and W. A. Weber
Treatment Monitoring by 18F-FDG PET/CT in Patients with Sarcomas: Interobserver Variability of Quantitative Parameters in Treatment-Induced Changes in Histopathologically Responding and Nonresponding Tumors
J. Nucl. Med., July 1, 2008; 49(7): 1038 - 1046.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
J. H.F. Rudd, K. S. Myers, S. Bansilal, J. Machac, C. A. Pinto, C. Tong, A. Rafique, R. Hargeaves, M. Farkouh, V. Fuster, et al.
Atherosclerosis Inflammation Imaging with 18F-FDG PET: Carotid, Iliac, and Femoral Uptake Reproducibility, Quantification Methods, and Recommendations
J. Nucl. Med., June 1, 2008; 49(6): 871 - 878.
[Abstract] [Full Text] [PDF]


Home page
RadioGraphicsHome page
C. Suzuki, H. Jacobsson, T. Hatschek, M. R. Torkzad, K. Boden, Y. Eriksson-Alm, E. Berg, H. Fujii, A. Kubo, and L. Blomqvist
Radiologic Measurements of Tumor Response to Treatment: Practical Approaches and Limitations
RadioGraphics, March 1, 2008; 28(2): 329 - 344.
[Abstract] [Full Text] [PDF]


Home page
J. Nucl. Med. Technol.Home page
D. C. Vines, H. Keller, J. D.P. Hoisak, and S. L. Breen
Quantitative PET Comparing Gated with Nongated Acquisitions Using a NEMA Phantom with Respiratory-Simulated Motion
J. Nucl. Med. Technol., December 1, 2007; 35(4): 246 - 251.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
J. Czernin and H. R. Schelbert
Introduction
J. Nucl. Med., January 1, 2007; 48(1_suppl): 2S - 3S.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2007 by the Society of Nuclear Medicine.